4.34
-0.0103(-0.24%)
Currency In USD
| Previous Close | 4.34 |
| Open | 4.34 |
| Day High | 4.34 |
| Day Low | 4.34 |
| 52-Week High | 5.91 |
| 52-Week Low | 3.36 |
| Volume | 2 |
| Average Volume | 5,766.4 |
| Market Cap | 162.3M |
| PE | -2.13 |
| EPS | -2.04 |
| Moving Average 50 Days | 4.1 |
| Moving Average 200 Days | 3.88 |
| Change | -0.01 |
If you invested $1000 in Molecular Partners AG (MOLN) since IPO date, it would be worth $220.87 as of December 24, 2025 at a share price of $4.34. Whereas If you bought $1000 worth of Molecular Partners AG (MOLN) shares 3 years ago, it would be worth $695.07 as of December 24, 2025 at a share price of $4.34.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Molecular Partners to Present at 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Dec 18, 2025 6:00 AM GMT
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics
Molecular Partners Forms Scientific Advisory Board to Accelerate Development of Targeted Radiotherapeutics
GlobeNewswire Inc.
Dec 11, 2025 12:00 PM GMT
Chaired by globally renowned nuclear medicine expert Prof. Ken Herrmann, M.D. Other Board members James Cook, Jason Lewis, Ph.D., and Michael Morris, M.D. bring significant clinical and industry expertise, supporting transition from early clinical va
Molecular Partners Presents Updated Data from Ongoing Phase 1/2a Trial of MP0533 in AML at ASH Annual Meeting
GlobeNewswire Inc.
Dec 07, 2025 12:00 PM GMT
Poster outlines clinical benefit with acceptable safety profile across 9 tested dosing regimensAccelerated step-up dosing and higher dosing frequency is feasible and results in increased exposure Six of eight responders presented with low bone marrow